WANTAI BIOLOGICAL(603392)2025-01-15 10:37Profit Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 86 million and 120 million yuan, a decrease of 116.168 million to 112.768 million yuan compared to the previous year, representing a decline of 93.11% to 90.38%[2]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -220 million and -155 million yuan, a decrease of 129.822 million to 123.322 million yuan compared to the previous year, reflecting a decline of 120.40% to 114.38%[3]. - The previous year's net profit attributable to shareholders of the parent company was 124.768 million yuan, with a total profit of 139.339 million yuan[5]. - The company emphasizes that the above forecast data is preliminary and subject to change, with the final audited financial data to be disclosed in the 2024 annual report[8]. - There are no significant uncertainties affecting the accuracy of this earnings forecast[7]. - The earnings forecast period is from January 1, 2024, to December 31, 2024[3]. - The earnings forecast has not been audited by a registered accountant[4]. Revenue Performance - The decline in profit is primarily due to the vaccine segment being affected by market adjustments, government procurement, and the expansion of the nine-valent HPV vaccine, leading to lower-than-expected sales and significant revenue and profit declines[6]. - The company achieved a 55% increase in overseas revenue compared to the same period last year through various channels to promote international market sales[6]. - The diagnostics segment benefited from the acceleration of major projects and collaborations with top 300 hospitals, showing rapid growth in sales revenue and profit compared to the previous year, excluding COVID-19 related business[6].